Hokko Chemical Industry Co., Ltd.

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Other

Hokko Chemical Co., Ltd.

Kenji Kanbe

Atsushi Takahashi

Yuichi Kita

Tetsuya Mori

Tomio Takeuchi

Wakako Ichikawa

Masanori Yamaguchi

Akihiro Tomoda

Tsuyoshi Tamamura

Kiyoshi Sato

Kiyoshi Hirazawa

Makoto Yoshida

Masanori Sanraizu Tatsunodai-101 Yamaguchi

It is intended to provide a novel NAD-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genusorand can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.

Method for producing scyllo-inositol

Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, inexpensive myo-inositol is used as a starting compound which is reacted with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. A biologically pure culture ofsp. AB 10215 strain is also provided which has a characteristic nature of being capable of converting myo-inositol into L-epi-2-inosose.

Process for producing L-epi-2-inosose and novel process for producing epi-inositol using microorganisms

Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, there is used inexpensive myo-inositol as a starting compound. That is, there is now developed a new process which comprises reacting myo-inositol with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. Further, a novel process is provided, which comprises reacting the so produced L-epi-2-inosose with a reducing agent made of an alkali metal boron hydride or any other alkali metal hydride in an aqueous reaction medium, to produce epi-inositol and myo-inositol, and then isolating epi-inositol from the resulting reaction product composed of the epi-inositol and myo-inositol.

Process for producing L-epi-2-inosose and novel process for producing epi-inositol

Processes for the preparation of D-chiro-inositol

Growing community of inventors

Yokohama, Japan

Kenji Kanbe